BONK is experiencing significant volatility and social media debate as investors navigate a recent treasury exploit that sparked concerns about security and future token value. While some community members advocate for holding or accumulating during dips, others remain deeply skeptical and are calling it a failed project, highlighting a sharp divide between those betting on a recovery and those warning of a long-term decline.

Iovance Biotherapeutics is surging on heavy trading volume as investors speculate on potential institutional accumulation or news ahead of upcoming earnings. The community is buzzing over the stock reclaiming the five-dollar level, with many viewing it as a critical threshold for institutional eligibility and a catalyst for a potential short squeeze.

Trump Media is trending following news that it is considering charging high monthly fees for early access to market-moving Truth Social posts, a move that has sparked intense debate among users about corporate ethics and potential market manipulation. Community members are actively clashing over the company's valuation, the political implications of its platform policies, and the broader influence of the Trump administration on market stability.

Applied Digital is experiencing intense volatility as investors weigh the company's strong long-term AI infrastructure backlog against a broader sector-wide correction that has aggressively compressed valuations. While some market participants are expressing frustration over the recent sell-off, the active community remains deeply divided between those viewing the pullback as a prime accumulation opportunity for long-term growth and those bracing for further downside volatility.

SoFi Technologies is experiencing heavy volatility as investors debate the impact of institutional accumulation against persistent short-selling pressure leading into upcoming quarterly earnings. While some community members remain focused on the company's long-term growth and platform expansion, others are reacting to aggressive price action and technical levels, leading to a polarized environment between long-term holders and opportunistic traders.

Lowe's shares are trending amid increased investor scrutiny as market participants prepare for upcoming earnings, with community sentiment split between concerns over sluggish DIY demand and optimism regarding potential rebounds from interest rate easing. Traders are heavily monitoring options flow and technical support levels, balancing a cautious macro outlook against strategic acquisitions aimed at expanding the company's Pro-focused market segment.

SOXL is currently experiencing significant volatility as investors debate whether the recent sharp pullback in the semiconductor sector represents a healthy consolidation or a deeper structural trend reversal. Community sentiment is heavily split, with many traders actively buying the dip based on long-term AI infrastructure growth expectations, while others warn of a potential liquidity trap and further downside risk amid broader market uncertainty.

General Fusion is capturing market attention as it transitions into the public markets via a business combination, sparking active debate among community members regarding its fusion technology milestones compared to competitors. While bulls highlight the company's backing by prominent investors, skeptics remain vocal about long development timelines and the risks inherent in fusion-focused microcaps.

Celsius is facing significant volatility and short interest pressure, with traders fiercely debating whether current price levels represent a generational buying opportunity or a deeper correction linked to sector competition and macroeconomic headwinds. Despite the downward pressure, the community remains divided, with long-term investors pointing to strong brand growth and international expansion via Pepsi distribution, while short-sellers highlight concerns over slowing core product momentum and potential market saturation.

Axsome Therapeutics is trending as investors eagerly await a pivotal regulatory decision for its agitation treatment in Alzheimer's patients, a massive addressable market that remains significantly underserved. The community is actively debating the stock's potential for a major breakout, focusing on the high-stakes binary outcome of the pending approval and the upcoming quarterly financial reports.